Rhythm Pharmaceuticals Q3 2024 Earnings Report $53.49 -0.81 (-1.49%) As of 03/27/2025 04:00 PM Eastern Earnings HistoryForecast Rhythm Pharmaceuticals EPS ResultsActual EPS-$0.73Consensus EPS -$0.80Beat/MissBeat by +$0.07One Year Ago EPS-$0.76Rhythm Pharmaceuticals Revenue ResultsActual Revenue$33.20 millionExpected Revenue$32.52 millionBeat/MissBeat by +$680.00 thousandYoY Revenue Growth+47.60%Rhythm Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/5/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseRYTM Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Remove Ads Rhythm Pharmaceuticals Earnings HeadlinesHC Wainwright Issues Negative Forecast for RYTM EarningsMarch 28 at 1:29 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Rhythm Pharmaceuticals (RYTM)March 27 at 3:15 PM | markets.businessinsider.comCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see this footage.) A lot of people believe the U.S. government is hiding aliens at the highly classified U.S. Air Force facility in Nevada known as “Area 51.”March 28, 2025 | Brownstone Research (Ad)Q2 Earnings Forecast for RYTM Issued By HC WainwrightMarch 27 at 1:49 AM | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given "Buy" Rating at HC WainwrightMarch 25 at 1:48 AM | americanbankingnews.com7RYTM : Analyst Expectations For Rhythm Pharmaceuticals&#...March 24, 2025 | benzinga.comSee More Rhythm Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rhythm Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rhythm Pharmaceuticals and other key companies, straight to your email. Email Address About Rhythm PharmaceuticalsRhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.View Rhythm Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
